TerminatedNot Applicable

Glucose Homeostasis in Pseudohypoparathyroidism

Stopped: COVID precautions prevented enrollment of healthy controls, funding ended.

United States14 participantsStarted 2019-06-19

Plain-language summary

It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown. In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.

Who can participate

Age range6 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of PHP1A/PPHP
✓. Age between 6 and 50 years old
✓. Gender
✓. Race
✓. Age (±2 years if \<25 years old or ±5 years if ≥25 years old)
✓. BMI (±2 kg/m2)
✓. Diabetes status

Exclusion criteria

✕. Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months
✕. Type 1 diabetes
✕. Type 2 diabetes treated with insulin or GLP-1 receptor agonists or A1c \>9%at their most recent clinic visit
✕. Pregnant or lactating women

What they're measuring

Insulin sensitivity (Si)

Timeframe: baseline

Trial details

NCT IDNCT03761290

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-04-30

View on ClinicalTrials.gov More Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism trials